- Home
- LUCD vs REVBW Comparison
LUCD vs REVBW Comparison
Compare LUCD & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- REVBW
- Stock Information
- Founded
- LUCD 2018
- REVBW N/A
- Country
- LUCD United States
- REVBW United States
- Employees
- LUCD N/A
- REVBW 9
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- REVBW Health Care
- Exchange
- LUCD Nasdaq
- REVBW Nasdaq
- Market Cap
- LUCD N/A
- REVBW N/A
- IPO Year
- LUCD 2021
- REVBW 2020
- Fundamental
- Price
- LUCD $1.21
- REVBW N/A
- Analyst Decision
- LUCD Strong Buy
- REVBW
- Analyst Count
- LUCD 4
- REVBW 0
- Target Price
- LUCD $3.75
- REVBW N/A
- AVG Volume (30 Days)
- LUCD 1.5M
- REVBW N/A
- Earning Date
- LUCD 05-12-2025
- REVBW N/A
- Dividend Yield
- LUCD N/A
- REVBW N/A
- EPS Growth
- LUCD N/A
- REVBW N/A
- EPS
- LUCD N/A
- REVBW N/A
- Revenue
- LUCD $4,346,000.00
- REVBW N/A
- Revenue This Year
- LUCD $121.84
- REVBW N/A
- Revenue Next Year
- LUCD $220.91
- REVBW N/A
- P/E Ratio
- LUCD N/A
- REVBW N/A
- Revenue Growth
- LUCD 79.00
- REVBW N/A
- 52 Week Low
- LUCD $0.63
- REVBW N/A
- 52 Week High
- LUCD $1.80
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- LUCD 42.45
- REVBW N/A
- Support Level
- LUCD $1.07
- REVBW N/A
- Resistance Level
- LUCD $1.80
- REVBW N/A
- Average True Range (ATR)
- LUCD 0.13
- REVBW 0.00
- MACD
- LUCD -0.05
- REVBW 0.00
- Stochastic Oscillator
- LUCD 19.18
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).